Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $916 | 6-8 weeks | |
50 mg | $1,190 | 6-8 weeks | |
100 mg | $1,860 | 6-8 weeks |
Description | Pirepemat (IRL752) fumarate can be used in Parkinson's disease study. Pirepemat is a cortical-preferring catecholamine transmission- and cognition-promoting agent [1] [2]. |
In vitro | IRL752 fumarate exhibits its strongest in vitro affinities primarily for serotonin (5-HT) and norepinephrine (NA)-related targets [2]. |
In vivo | IRL752 fumarate, administered subcutaneously at dosages ranging from 3.7 to 100 μmol/kg, does not significantly influence acute hyperdopaminergic or hypoglutamatergic motor responses. However, it effectively reverses impairments associated with reduced monoaminergic function. In normal rats tested 30 minutes after administration, IRL752 induced dose-dependent and region-specific changes in brain monoamine transmission indices and gene expression, showcasing its potential in modulating neurotransmitter system dysfunctions. |
Molecular Weight | 329.3 |
Formula | C15H17F2NO5 |
Cas No. | 2251806-70-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.